Truist Securities Maintains Hold on Inari Medical, Raises Price Target to $70
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Richard Newitter has maintained a Hold rating on Inari Medical (NASDAQ:NARI) and increased the price target from $65 to $70.
December 22, 2023 | 2:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities has maintained a Hold rating on Inari Medical but raised the price target from $65 to $70, indicating a positive outlook on the stock's value.
The increase in price target by Truist Securities suggests that the analyst sees potential for Inari Medical's stock price to rise, which could positively influence investor sentiment and the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100